This quick video takes a look at Mylan ahead of its earnings report. The pharma company has been under pressure for much of 2016 while a bottom 33% industry rank isn’t helping matters either.

Even more troubling than the weak industry rank is the rank for MYL stock. Shares of Mylan are now in ‘sell’ territory, while the VGM score for the stock is just a ‘C’. Additionally, the stock has a negative earnings ESP, which can be a harbinger of a miss in earnings season.

However, investors should note that while estimates are definitely trending lower, MYL does have a history of beating earnings expectations. The company has missed just twice in the past five years, so history is definitely on Mylan’s side, though it could be a case where the outlook and the sector perception weigh on the shares more than anything.

MYLAN NV Price, Consensus and EPS Surprise

MYLAN NV Price, Consensus and EPS Surprise | MYLAN NV Quote

Mylan reports on November 9^th after the bell, and we are looking for earnings of $1.50 per share. Make sure to watch the video for a quick guide to MYL heading into the report, but if you want to learn more about trading in earnings season, check out our Zacks Live Trader below for additional information:

Confidential from Zacks

Would you like to access Zacks' 2 best trades that are not available to the public? Zacks Executive VP, Steve Reitmeister knows which of our experts has the hottest hand and when key trades are about to be triggered. Today he is prepared to pass the Best of Our Best along to you. See these timely buys now >>